Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant and Adjuvant Therapy for Resectable Pancreatic Cancer
NCT00609336Phase 2Completed
- Sponsor
- University of Washington
- Start
- Jan 2008
- Primary completion
- Nov 2014
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gemcitabine, docetaxel, capecitabine, oxaliplatin in pancreatic adenocarcinoma (PDAC), sponsored by University of Washington. Started Jan 2008; status: completed.
02
Drugs
gemcitabinedocetaxelcapecitabineoxaliplatin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00609336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00609336.